After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer

Serial biotech investor Kevin Tang previously unsuccessfully tried to buy Kezar Life Sciences via Concentra Biosciences, a biotech consolidation company owned by the venture capital firm he runs.